Literature DB >> 14506026

In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

D Andes1, K Marchillo, T Stamstad, R Conklin.   

Abstract

In vivo studies have described the pharmacodynamic (PD) characteristics of several triazoles. These investigations have demonstrated that the 24-h area under the concentration-time curve (AUC)/MIC ratio is the critical pharmacokinetic (PK)-PD parameter associated with treatment efficacy. Further analyses from these in vivo studies have demonstrated that a triazole free drug 24-h AUC/MIC of 20 to 25 is predictive of treatment success. We used a neutropenic murine model of disseminated Candida albicans infection to similarly characterize the PK-PD of the new triazole voriconazole. PK and PD parameters (percentage of time that the concentration remains above the MIC [T > MIC], AUC/MIC ratio, and peak level in serum/MIC ratio) were correlated with in vivo efficacy, as measured by the organism number in kidney cultures after 24 h of therapy. Voriconazole kinetics and protein binding were studied in infected neutropenic mice. Peak level/dose and AUC/dose values ranged from 0.1 to 0.2 and 0.1 to 0.7, respectively. The serum elimination half-life ranged from 0.7 to 2.9 h. The level of protein binding in mouse serum was 78%. Treatment efficacy with the four dosing intervals studied was similar, supporting the AUC/MIC ratio as the PK-PD parameter predictive of efficacy. Nonlinear regression analysis also suggested that the AUC/MIC ratio was strongly predictive of treatment outcomes (R(2) for AUC/MIC ratio = 82%, R(2) for peak level/MIC ratio = 63%, R(2) for T > MIC = 75%). Similar studies were conducted with nine additional C. albicans isolates with various voriconazole susceptibilities (MICs, 0.007 to 0.25 micro g/ml) to determine if a similar 24-h AUC/MIC ratio was associated with efficacy. The voriconazole free drug AUC/MIC ratios were similar for all of the organisms studied (range, 11 to 58; mean +/- standard deviation, 24 +/- 17 [P = 0.45]). These AUC/MIC ratios observed for free drug are similar to those observed for other triazoles in this model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506026      PMCID: PMC201151          DOI: 10.1128/AAC.47.10.3165-3169.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Efficacy of voriconazole in treatment of murine pulmonary blastomycosis.

Authors:  A M Sugar; X P Liu
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  Influence of binding on the pharmacologic activity of antibiotics.

Authors:  C M Kunin; W A Craig; M Kornguth; R Monson
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

3.  Clinical pharmacology of the new penicillins. 1. The importance of serum protein binding in determining antimicrobial activity and concentration in serum.

Authors:  C M Kunin
Journal:  Clin Pharmacol Ther       Date:  1966 Mar-Apr       Impact factor: 6.875

4.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

5.  Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular fluid.

Authors:  D M Ryan; B Hodges; G R Spencer; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

6.  Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.

Authors:  T E Rogers; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

7.  Resistance mechanisms in clinical isolates of Candida albicans.

Authors:  Theodore C White; Scott Holleman; Francis Dy; Laurence F Mirels; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice.

Authors:  J W Van t Wout; H Mattie; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

9.  Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Authors:  L Purkins; N Wood; P Ghahramani; K Greenhalgh; M J Allen; D Kleinermans
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

View more
  80 in total

Review 1.  Triazole antifungal agents in invasive fungal infections: a comparative review.

Authors:  Cornelia Lass-Flörl
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 2.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

3.  Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.

Authors:  Lena E Friberg; Patanjali Ravva; Mats O Karlsson; Ping Liu
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

4.  Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Authors:  Lorena Baietto; Antonio D'Avolio; Giusi Ventimiglia; Francesco Giuseppe De Rosa; Marco Siccardi; Marco Simiele; Mauro Sciandra; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

5.  Steady-state plasma pharmacokinetics of oral voriconazole in obese adults.

Authors:  Manjunath P Pai; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

6.  Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.

Authors:  Naveen Mangal; Issam S Hamadeh; Meghan J Arwood; Larisa H Cavallari; Tanay S Samant; Kenneth P Klinker; Jurgen Bulitta; Stephan Schmidt
Journal:  Clin Pharmacol Ther       Date:  2018-02-13       Impact factor: 6.875

7.  Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.

Authors:  Wendy W J van de Sande; Ron A A Mathot; Marian T ten Kate; Wim van Vianen; Mehri Tavakol; Bart J A Rijnders; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

8.  Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans.

Authors:  Scott W Mueller; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2011-03-26

9.  Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies.

Authors:  K Nomura; Y Fujimoto; Y Kanbayashi; K Ikawa; M Taniwaki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-18       Impact factor: 3.267

10.  Voriconazole pharmacokinetics and pharmacodynamics in children.

Authors:  Michael Neely; Teresa Rushing; Andrea Kovacs; Roger Jelliffe; Jill Hoffman
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.